Eupraxia Pharmaceuticals (EPRX) Invested Capital (2022 - 2024)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Invested Capital of $10.3 million for Q4 2023, up 12914.69% year-over-year from N/an in Q4 2022, and up 12914.69% quarter-over-quarter from $79418.0 in Q4 2022.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Invested Capital (2022 - 2024) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Invested Capital for 2 consecutive years, with $10.3 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Invested Capital rose 12914.69% year-over-year to $10.3 million; the TTM figure through Sep 2024 stood at $10.3 million (up 12914.69% YoY), while the FY2023 annual figure was $10.3 million, up 12914.69% from the prior year.
- Invested Capital grew to $10.3 million in Q4 2023 per EPRX's latest filing, from $79418.0 in the prior quarter.
- Across five years, Invested Capital topped out at $10.3 million in Q4 2023 and bottomed at $79418.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Eupraxia Pharmaceuticals | 318.85 Mn | 318.85 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 31.84 Mn |
| Jun 30, 2024 | 13.36 Mn |
| Mar 31, 2024 | 18.15 Mn |
| Dec 31, 2023 | 955,035.00 |
| Dec 31, 2022 | 7.35 Mn |